PSMD14 and Miyoshi myopathy: Its expression is increased and associated with poor outcomes in various cancers, including MM [7], hepatocellular carcinoma (HCC) [8], esophageal squamous cell carcinoma (ESCC) [9], lung adenocarcinoma [10], and breast cancer [11], suggesting that PSMD14 may serve as a potential prognostic marker and therapeutic target in human cancers.